Patients with head and neck cancer who have never smoked have much better survival rates after radiation therapy than patients with a history of smoking, new research from UC Davis Cancer Center has found.
The study by Allen M. Chen and colleagues in the UC Davis radiation oncology and otolaryngology departments is among the first of its kind to examine prognosis differences based on smoking history in patients with head and neck cancer who are treated with radiation therapy.
The study, published online in American Journal of Clinical Oncology, found that patients with a history of smoking were more likely to die from their disease and more likely to experience a recurrence after radiation therapy than those without a smoking history.
“There is something unique about the biology of head and neck cancers among non-smokers that makes them more amenable to cure by radiation therapy,” said Chen. “These tumors just melt after a few doses of radiation. If we could understand why, there would be important implications for new drugs and treatments.”
Chen suspects one possible explanation for the difference in response to radiation is human papillomavirus (HPV), a sexually transmitted disease that has been highly associated with head and neck cancer in people who have never smoked.
“The most common theory is that these tumors express a characteristic viral antigen on the cell surface that makes the immune system recognize the cancers more readily, which may enhance the effects of radiation,” he said. “Another theory is that patients who have never smoked and who have HPV-related tumors have fewer mutations in key genes that are critical for radiation response.”
Chen compared 70 patients treated at the UC Davis Department of Radiation Oncology with newly diagnosed, non-metastatic squamous cell carcinoma of the mouth and throat who had a history of smoking with 70 patients with similar diagnoses who reported they had never smoked. Patients who continued to smoke during treatment were not included in the study. Subjects were evenly matched based on age, gender, ethnicity, primary tumor site, disease stage and treatment history.
The analysis found that 14 of the 70 never-smokers experienced a recurrence of their disease compared to 26 patients who had a history of smoking. In addition, 82 percent of never-smokers were disease-free after three years compared to 65 percent of patients who had smoked. Also, those who had never smoked had a lower incidence of complications related to treatment than those who had smoked.
Chen said the next step in the research is to identify biological or genetic differences among smokers and never-smokers diagnosed with head and neck cancers and treated with radiation therapy that might account for the differences in prognosis.
“We are in the process of conducting several laboratory experiments designed to better understand why cancers arising from never smokers are so exquisitely radiosensitive,” Chen said.
UC Davis Cancer Center is the only National Cancer Institute- designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its top specialists provide compassionate, comprehensive care for more than 9,000 adults and children every year, and offer patients access to more than 150 clinical trials at any given time. Its innovative research program includes more than 280 scientists at UC Davis and Lawrence Livermore National Laboratory. The unique partnership, the first between a major cancer center and national laboratory, has resulted in the discovery of new tools to diagnose and treat cancer. Through the Cancer Care Network, UC Davis is collaborating with a number of hospitals and clinical centers throughout the Central Valley and Northern California regions to offer the latest cancer-care services.
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences